Inventor
ELBAUM DANIEL
US42 patents
⚠️ This page may combine multiple inventors who share the name “ELBAUM DANIEL”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
RA PHARMACEUTICALS INC
16 patentsUS10588936B2Mar 17, 2020
Modulators of complement activity
RA PHARMACEUTICALS INC13 citations93
US10328115B2Jun 25, 2019
Modulators of complement activity
RA PHARMACEUTICALS INC15 citations93
US10106579B2Oct 23, 2018
Modulation of complement activity
RA PHARMACEUTICALS INC19 citations93
US10435438B2Oct 8, 2019
Modulation of complement activity
RA PHARMACEUTICALS INC12 citations92
US10208089B2Feb 19, 2019
Modulation of complement activity
RA PHARMACEUTICALS INC12 citations92
US9937222B2Apr 10, 2018
Modulators of complement activity
RA PHARMACEUTICALS INC14 citations92
US11014965B2May 25, 2021
Modulation of complement activity
RA PHARMACEUTICALS INC3 citations83
US10918691B2Feb 16, 2021
Modulators of complement activity
RA PHARMACEUTICALS INC2 citations72
US10272132B2Apr 30, 2019
Peptide and peptidomimetic inhibitors
RA PHARMACEUTICALS INC1 citations72
US12239684B2Mar 4, 2025
Modulators of complement activity
RA PHARMACEUTICALS INC0 citations62
US11965040B2Apr 23, 2024
Modulation of complement activity
RA PHARMACEUTICALS INC0 citations62
US11707503B2Jul 25, 2023
Modulators of complement activity
RA PHARMACEUTICALS INC0 citations62
US11535650B1Dec 27, 2022
Modulation of complement activity
RA PHARMACEUTICALS INC0 citations62
US9644004B2May 9, 2017
Peptide and peptidomimetic inhibitors
RA PHARMACEUTICALS INC1 citations61
US9238676B2Jan 19, 2016
Peptide and peptidomimetic inhibitors
RA PHARMACEUTICALS INC2 citations61
US9999650B2Jun 19, 2018
Peptide and peptidomimetic inhibitors
RA PHARMACEUTICALS INC0 citations51
AMGEN INC
11 patentsUS6878714B2Apr 12, 2005
Substituted alkylamine derivatives and methods of use
AMGEN INC85 citations97
US6995162B2Feb 7, 2006
Substituted alkylamine derivatives and methods of use
AMGEN INC48 citations95
US7105682B2Sep 12, 2006
Substituted amine derivatives and methods of use
AMGEN INC29 citations92
US7102009B2Sep 5, 2006
Substituted amine derivatives and methods of use
AMGEN INC49 citations92
US7074789B2Jul 11, 2006
Kinase inhibitors
AMGEN INC25 citations92
US7531553B2May 12, 2009
Heterocyclic compounds and methods of use
AMGEN INC44 citations91
US6495558B1Dec 17, 2002
Kinase inhibitors
AMGEN INC18 citations84
US7514564B2Apr 7, 2009
Substituted amine derivatives and methods of use
AMGEN INC16 citations83
US7442698B2Oct 28, 2008
Substituted heterocyclic compounds and methods of use
AMGEN INC11 citations83
US7320992B2Jan 22, 2008
Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
AMGEN INC15 citations83
US7101868B2Sep 5, 2006
Substituted arylamine derivatives and methods of use
AMGEN INC20 citations83
CORNERSTONE THERAPEUTICS INC
4 patentsUS7943622B2May 17, 2011
Piperazines, pharmaceutical compositions and methods of use thereof
CORNERSTONE THERAPEUTICS INC3 citations62
US8008499B2Aug 30, 2011
Anabaseine derivatives, pharmaceutical compositions and methods of use thereof
CORNERSTONE THERAPEUTICS INC4 citations61
US9428522B2Aug 30, 2016
Piperazines, pharmaceutical compositions and methods of use thereof
CORNERSTONE THERAPEUTICS INC1 citations51
US7662965B2Feb 16, 2010
Anabaseine derivatives, pharmaceutical compositions and method of use thereof
CORNERSTONE THERAPEUTICS INC1 citations51
UNIV PENNSYLVANIA
3 patentsUS6387890B1May 14, 2002
Compositions and methods for inhibiting arginase activity
UNIV PENNSYLVANIA18 citations90
US6284544B1Sep 4, 2001
Determination of metal ions in solution by photoluminescence anisotropy
UNIV PENNSYLVANIA21 citations90
US6723710B2Apr 20, 2004
Compositions for inhibiting arginase activity
UNIV PENNSYLVANIA12 citations71